Multicentric, observational, transversal study to describe the clinical profile of patients with metastatic breast cancer (MBC) treated with first-line bevacizumab (TRANSBREAST): Preliminary results.

1143 Background: Following the approval of bevacizumab for the treatment of MBC, this study was devised to identify the profile of patients (pt) treated under real conditions of use, their relationship with the regime used and the MBC subtypes by their genetic signature and tolerability of treatment. Methods: Multicentric observational transversal study in 40 centers. We present the results from the first 108 pts who received at least one dose of bevacizumab. Results: Of the women treated, 98.1% were Caucasian, with a mean age of 50.7 years (30-82) and ECOG 0-1 in 88%. In terms of prior history, 3.7% suffered from cardiopathies, 11.1% vascular disorders and 4.8% had kidney pathology. Neoadjuvant or adjuvant chemotherapy (CT) was given to 88% of them. The predominant histology was infiltrating ductal (82%) and histological grade 3 (49%). Positive results for hormone receptors were found in 68.5%, of which 65% were luminal A and 3.5% luminal B; 3.5% were HER2 positive, while 28% were triple negative. The di...